CMPX Quote, Financials, Valuation and Earnings

Arcutis Biotherapeutics, Inc. has a net margin of -1538.35% compared to Compass Therapeutics, Inc.'s net margin of 7.47%. Compass Therapeutics, Inc.'s return on equity of -48.62% beat Arcutis Biotherapeutics, Inc.'s return on equity of -29.4%.

Compass Therapeutics, Inc. has a consensus price target of $12.62, signalling upside risk potential of 134.92%. On the other hand Arcutis Biotherapeutics, Inc. has an analysts' consensus of $31.63 which suggests that it could grow by 8.9%. Given that Compass Therapeutics, Inc. has higher upside potential than Arcutis Biotherapeutics, Inc., analysts believe Compass Therapeutics, Inc. is more attractive than Arcutis Biotherapeutics, Inc..

Compass Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Arcutis Biotherapeutics, Inc. has a beta of 1.710, suggesting its more volatile than the S&P 500 by 70.962%.

Compass Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Arcutis Biotherapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Compass Therapeutics, Inc. pays -- of its earnings as a dividend. Arcutis Biotherapeutics, Inc. pays out -- of its earnings as a dividend.

Compass Therapeutics, Inc. quarterly revenues are --, which are smaller than Arcutis Biotherapeutics, Inc. quarterly revenues of $99.2M. Compass Therapeutics, Inc.'s net income of -$14.3M is lower than Arcutis Biotherapeutics, Inc.'s net income of $7.4M. Notably, Compass Therapeutics, Inc.'s price-to-earnings ratio is -- while Arcutis Biotherapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Compass Therapeutics, Inc. is -- versus 11.63x for Arcutis Biotherapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Praxis Precision Medicines, Inc. has a net margin of -1538.35% compared to Compass Therapeutics, Inc.'s net margin of -786.27%. Compass Therapeutics, Inc.'s return on equity of -48.62% beat Praxis Precision Medicines, Inc.'s return on equity of -67.75%.

Compass Therapeutics, Inc. has a consensus price target of $12.62, signalling upside risk potential of 134.92%. On the other hand Praxis Precision Medicines, Inc. has an analysts' consensus of $449.13 which suggests that it could grow by 56.82%. Given that Compass Therapeutics, Inc. has higher upside potential than Praxis Precision Medicines, Inc., analysts believe Compass Therapeutics, Inc. is more attractive than Praxis Precision Medicines, Inc..

Compass Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Praxis Precision Medicines, Inc. has a beta of 2.851, suggesting its more volatile than the S&P 500 by 185.093%.

Compass Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Praxis Precision Medicines, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Compass Therapeutics, Inc. pays -- of its earnings as a dividend. Praxis Precision Medicines, Inc. pays out -- of its earnings as a dividend.

Compass Therapeutics, Inc. quarterly revenues are --, which are smaller than Praxis Precision Medicines, Inc. quarterly revenues of --. Compass Therapeutics, Inc.'s net income of -$14.3M is higher than Praxis Precision Medicines, Inc.'s net income of -$73.9M. Notably, Compass Therapeutics, Inc.'s price-to-earnings ratio is -- while Praxis Precision Medicines, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Compass Therapeutics, Inc. is -- versus 810.58x for Praxis Precision Medicines, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Regeneron Pharmaceuticals, Inc. has a net margin of -1538.35% compared to Compass Therapeutics, Inc.'s net margin of 38.89%. Compass Therapeutics, Inc.'s return on equity of -48.62% beat Regeneron Pharmaceuticals, Inc.'s return on equity of 15.37%.

Compass Therapeutics, Inc. has a consensus price target of $12.62, signalling upside risk potential of 134.92%. On the other hand Regeneron Pharmaceuticals, Inc. has an analysts' consensus of $797.27 which suggests that it could grow by 2.7%. Given that Compass Therapeutics, Inc. has higher upside potential than Regeneron Pharmaceuticals, Inc., analysts believe Compass Therapeutics, Inc. is more attractive than Regeneron Pharmaceuticals, Inc..

Compass Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Regeneron Pharmaceuticals, Inc. has a beta of 0.390, suggesting its less volatile than the S&P 500 by 60.965%.

Compass Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Regeneron Pharmaceuticals, Inc. offers a yield of 0.45% to investors and pays a quarterly dividend of $0.88 per share. Compass Therapeutics, Inc. pays -- of its earnings as a dividend. Regeneron Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Compass Therapeutics, Inc. quarterly revenues are --, which are smaller than Regeneron Pharmaceuticals, Inc. quarterly revenues of $3.8B. Compass Therapeutics, Inc.'s net income of -$14.3M is lower than Regeneron Pharmaceuticals, Inc.'s net income of $1.5B. Notably, Compass Therapeutics, Inc.'s price-to-earnings ratio is -- while Regeneron Pharmaceuticals, Inc.'s PE ratio is 18.59x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Compass Therapeutics, Inc. is -- versus 6.00x for Regeneron Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Stoke Therapeutics, Inc. has a net margin of -1538.35% compared to Compass Therapeutics, Inc.'s net margin of -360.68%. Compass Therapeutics, Inc.'s return on equity of -48.62% beat Stoke Therapeutics, Inc.'s return on equity of 13.95%.

Compass Therapeutics, Inc. has a consensus price target of $12.62, signalling upside risk potential of 134.92%. On the other hand Stoke Therapeutics, Inc. has an analysts' consensus of $34.25 which suggests that it could grow by 10.84%. Given that Compass Therapeutics, Inc. has higher upside potential than Stoke Therapeutics, Inc., analysts believe Compass Therapeutics, Inc. is more attractive than Stoke Therapeutics, Inc..

Compass Therapeutics, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Stoke Therapeutics, Inc. has a beta of 1.102, suggesting its more volatile than the S&P 500 by 10.227%.

Compass Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Stoke Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Compass Therapeutics, Inc. pays -- of its earnings as a dividend. Stoke Therapeutics, Inc. pays out -- of its earnings as a dividend.

Compass Therapeutics, Inc. quarterly revenues are --, which are smaller than Stoke Therapeutics, Inc. quarterly revenues of $10.6M. Compass Therapeutics, Inc.'s net income of -$14.3M is higher than Stoke Therapeutics, Inc.'s net income of -$38.3M. Notably, Compass Therapeutics, Inc.'s price-to-earnings ratio is -- while Stoke Therapeutics, Inc.'s PE ratio is 46.83x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Compass Therapeutics, Inc. is -- versus 8.77x for Stoke Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.